Fig. 6: Inhibitory mechanism of riluzole against the glutamatergic system in melanoma. | Oncogenesis

Fig. 6: Inhibitory mechanism of riluzole against the glutamatergic system in melanoma.

From: Participation of xCT in melanoma cell proliferation in vitro and tumorigenesis in vivo

Fig. 6

EAAT-1 and xCT participate in the maintenance of glutamate homeostasis in melanoma. Riluzole inhibits glutamate release utilized for both glutamate circulation and GRM1-mediated proliferation in melanoma. xCT, cystine/ glutamate antiporter; EAAT-1, excitatory amino acid transporter 1; GRM1, metabotropic glutamate receptor 1; GSH, glutathione

Back to article page